Takeda Pharmaceutical Company Limited (TAK)
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
$17.81−0.28%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $56.9B
- Forward P/E
- 33.6
- Dividend yield
- 3.5%
- 52-week range
- $12.99 – $19.10
- 52-week change
- +23.51%
- EPS (trailing)
- −$0.34
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Oct 29, 2026
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr.
Headquarters: Chuo, Japan · 47,029 employees · takeda.com